[ CAS No. 88095-61-8 ] {[proInfo.proName]}

Name: 88095-61-8|1-Benzyl-4-nitro-1H-pyrazole|97%
Brand: Ambeed
SKU: A262393
Price: 11.0 USD
Availability: InStock
Rating: 91 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 88095-61-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 88095-61-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 88095-61-8 ]

SDS Specification

Alternatived Products of [ 88095-61-8 ]

Product Details of [ 88095-61-8 ]

CAS No. :	88095-61-8	MDL No. :	MFCD03087886
Formula :	C₁₀H₉N₃O₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	IYZHZCMFLIKMSN-UHFFFAOYSA-N
M.W :	203.20	Pubchem ID :	973645
Synonyms :

Calculated chemistry of [ 88095-61-8 ]

Physicochemical Properties

Num. heavy atoms :	15
Num. arom. heavy atoms :	11
Fraction Csp3 :	0.1
Num. rotatable bonds :	3
Num. H-bond acceptors :	3.0
Num. H-bond donors :	0.0
Molar Refractivity :	56.8
TPSA :	63.64 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	Yes
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.36 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.61
Log Po/w (XLOGP3) :	1.66
Log Po/w (WLOGP) :	1.84
Log Po/w (MLOGP) :	1.49
Log Po/w (SILICOS-IT) :	-0.38
Consensus Log Po/w :	1.24

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.49
Solubility :	0.657 mg/ml ; 0.00323 mol/l
Class :	Soluble
Log S (Ali) :	-2.61
Solubility :	0.499 mg/ml ; 0.00245 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-2.72
Solubility :	0.389 mg/ml ; 0.00191 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	2.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.93

Safety of [ 88095-61-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 88095-61-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 88095-61-8 ]
Downstream synthetic route of [ 88095-61-8 ]

[ 88095-61-8 ] Synthesis Path-Upstream 1~4

1
[ 88095-61-8 ]
[ 28466-62-8 ]

Reference： [1] Patent: US2010/120874, 2010, A1, . Location in patent: Page/Page column 28
[2] Journal of Medicinal Chemistry, 2014, vol. 57, # 13, p. 5714 - 5727
[3] Journal of Medicinal Chemistry, 2015, vol. 58, # 9, p. 3806 - 3816
[4] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 14, p. 2382 - 2390

2
[ 50877-42-4 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
63%	With nitric acid In tetrahydrofuran; water at 20℃; for 3.5 h;	General procedure: To iodopyrazole (1 mmol) dissolved in THF (10 mL), Fuajasite (250 mg) was added. Nitric acid (d 1.52 g/cm³, 10 mL) was added slowly and the mixture was stirred at room temperature for required time. The catalyst was recovered by filtration and the filtrate was extracted repeatedly with dichloromethane. The solvent was removed under vacuum to obtain nitropyrazole.

Reference： [1] Synthetic Communications, 2012, vol. 42, # 23, p. 3463 - 3471
[2] Catalysis Communications, 2013, vol. 42, p. 35 - 39

3
[ 2075-46-9 ]
[ 100-39-0 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
95%	Stage #1: With sodium hydride In N,N-dimethyl-formamide; mineral oil at 0 - 20℃; Inert atmosphere Stage #2: at 0 - 20℃; for 12 h; Inert atmosphere	a) 1-Benzyl-4-nitro-1H-pyrazole To a solution of 4-nitro-1H-pyrazole (283 mg, 2.5 mmol) in dry DMF (5 ml) under an argon atmosphere was added NaH (120 mg, 2.75 mmol) in small portions at 0° C. The reaction mixture was stirred at rt for 1 hour, cooled again to 0° C. before benzyl bromide (300 μl, 2.5 mmol) was added and stirred at rt for 12 h. The mixture was diluted with water, extracted with ethyl acetate and the product was purified by chromatography on silica gel using heptane/ethyl acetate as eluent. The title compound was obtained as light yellow oil (484 mg, 95percent). MS ISP (m/e): 226.3 (100) [(M+Na)⁺].

Reference： [1] Journal of Medicinal Chemistry, 2014, vol. 57, # 13, p. 5714 - 5727
[2] Patent: US2010/120874, 2010, A1, . Location in patent: Page/Page column 27-28

4
[ 2075-46-9 ]
[ 620-05-3 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
98%	With potassium carbonate In N,N-dimethyl-formamide at 25℃; for 16 h;	General procedure: To a stirred solution of 4-nitroimidazole or 4-nitropyrazole (1.00 g, 8.84 mmol) in DMF (6.00 mL) at 25°C were added K2CO3 (1.47 g, 10.6 mmol) and alkyl iodide(10.6 mmol). After stirring for 16 h at 25 °C, the reactionmixture was treated with water (15 mL) and EtOAc (20 mL)and transferred to a 125 mL separatory funnel. The organiclayer was collected and the aqueous layer was extracted withEtOAc (25 mL × 2). The combined organic layers werewashed with brine (20 mL), dried over sodium sulfate andfiltered. The filtrate was concentrated, and the residue waspurified by flash column chromatography to provide thecorresponding alkyl azole.

Reference： [1] Bulletin of the Korean Chemical Society, 2014, vol. 35, # 10, p. 3009 - 3014
[2] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 14, p. 2382 - 2390

[ 88095-61-8 ] Synthesis Path-Downstream 1~67

2
[ 88095-61-8 ]
[ 28466-62-8 ]

Yield	Reaction Conditions	Operation in experiment
86%	With palladium 10% on activated carbon; hydrogen; In methanol; at 15℃; for 16h;Inert atmosphere;	Step 2: Preparation of 1-benzylpyrazol-4-amine To a solution of 1-benzyl-4-nitro-pyrazole (1.50 g, 7.38 mmol) in methanol (10 mL) was added palladium on activated carbon (0.500 g, 10% by weight) under nitrogen. The suspension was purged with hydrogen several times. The mixture was stirred under hydrogen balloon at 15 C. for 16 h, then purged with nitrogen and filtrated. The filtrate was concentrated in vacuo to give 1-benzylpyrazol-4-amine (1.10 g, 6.35 mmol, 86%) as a pink solid. LCMS (ESI) m/z: 174.1 [M+H]+.
	With hydrogen;1% Pd/C; at 20℃; for 12h;Inert atmosphere;	b) 1-Benzyl-1H-pyrazol-4-ylamine A mixture of 1-benzyl-4-nitro-1H-pyrazole (33 mg, 0.162 mmol) and 10% Pd/C (10 mg) was stirred under an hydrogen atmosphere at rt for 12 h. The catalyst was filtered off, washed with methanol and the solvent was removed under reduced pressure to give the title compound as dark brown oil (27.4 mg, 97%). MS ISP (m/e): 174.2.3 (100) [(M+H)+].
	With hydrazine hydrate; palladium 10% on activated carbon; In ethanol; at 80℃; for 0.166667h;	General procedure: 80% hydrazine hydrate (1 mL) and 10% palladium charcoal (0.04 g) were added to a solution of 2a (2 mmol) in ethanol (5 mL). The reaction was hated to 80C for 10 min and filltered by celite. The filtrate was dried by sodium sulfate, and concentrated in vacuum to afford compound 3a, which were used without further purification.

Reference： [1]Patent: US2019/330198,2019,A1 .Location in patent: Paragraph 0585; 1112
[2]Patent: US2010/120874,2010,A1 .Location in patent: Page/Page column 28
[3]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727
[4]Journal of Medicinal Chemistry,2015,vol. 58,p. 3806 - 3816
[5]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390
[6]ChemMedChem,2018,vol. 13,p. 2558 - 2566

3
[ 2075-46-9 ]
[ 100-39-0 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
95%		a) 1-Benzyl-4-nitro-1H-pyrazole To a solution of 4-nitro-1H-pyrazole (283 mg, 2.5 mmol) in dry DMF (5 ml) under an argon atmosphere was added NaH (120 mg, 2.75 mmol) in small portions at 0 C. The reaction mixture was stirred at rt for 1 hour, cooled again to 0 C. before benzyl bromide (300 mul, 2.5 mmol) was added and stirred at rt for 12 h. The mixture was diluted with water, extracted with ethyl acetate and the product was purified by chromatography on silica gel using heptane/ethyl acetate as eluent. The title compound was obtained as light yellow oil (484 mg, 95%). MS ISP (m/e): 226.3 (100) [(M+Na)+].
78%		Step 1: Preparation of 1-benzyl-4-nitro-pyrazole To a stirred solution of 4-nitro-1H-pyrazole (2.00 g, 17.7 mmol) in N,N-dimethylformamide (15 mL) was added sodium hydride (0.778 g, 19.0 mmol, 60% purity in mineral oil) at 0 C. The reaction mixture was stirred at 15 C. for 1 h and then cooled to 0 C. before benzyl bromide (2.10 mL, 17.7 mmol) was added. The reaction mixture was warmed to 15 C. and stirred for 15 h then quenched by adding ice water (5 mL) and extracted with ethyl acetate (15 mL3). The combined organic layers were washed with water (10 mL2) and brine (5 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (ISCO, 20 g silica, 0-30% ethyl acetate in petroleum ether, gradient over 20 min) to give 1-benzyl-4-nitro-pyrazole (2.80 g, 13.8 mmol, 78%) as a white solid. 1H NMR (400 MHz, Chloroform-d) delta 8.10 (s, 1H), 8.04 (s, 1H), 7.45-7.39 (m, 3H), 7.32-7.28 (m, 2H), 5.31 (s, 2H); LCMS (ESI) m/z: 204.1 [M+H]+.

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727
[2]Patent: US2010/120874,2010,A1 .Location in patent: Page/Page column 27-28
[3]Patent: US2019/330198,2019,A1 .Location in patent: Paragraph 0853; 1110

4
[ 88095-61-8 ]
[ 90920-49-3 ]

Reference： [1]Journal of Heterocyclic Chemistry,2013,vol. 50,p. 1322 - 1327
[2]Catalysis Communications,2012,vol. 19,p. 37 - 41

5
[ 50877-42-4 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
63%	With nitric acid; In tetrahydrofuran; water; at 20℃; for 3.5h;	General procedure: To iodopyrazole (1 mmol) dissolved in THF (10 mL), Fuajasite (250 mg) was added. Nitric acid (d 1.52 g/cm3, 10 mL) was added slowly and the mixture was stirred at room temperature for required time. The catalyst was recovered by filtration and the filtrate was extracted repeatedly with dichloromethane. The solvent was removed under vacuum to obtain nitropyrazole.

Reference： [1]Synthetic Communications,2012,vol. 42,p. 3463 - 3471
[2]Catalysis Communications,2013,vol. 42,p. 35 - 39

6
[ 88095-61-8 ]
[ 1557248-86-8 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

7
[ 88095-61-8 ]
[ 1557248-80-2 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

8
[ 88095-61-8 ]
[ 1557248-81-3 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

9
[ 88095-61-8 ]
[ 1557249-03-2 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

10
[ 88095-61-8 ]
[ 1557248-89-1 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

11
[ 88095-61-8 ]
[ 1557249-64-5 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

12
[ 88095-61-8 ]
[ 1557249-05-4 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

13
[ 88095-61-8 ]
[ 1557248-91-5 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

14
[ 88095-61-8 ]
[ 1557250-11-9 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

15
[ 88095-61-8 ]
[ 1557232-24-2 ]
[ 1557232-26-4 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

16
[ 88095-61-8 ]
[ 1557234-60-2 ]
[ 1557234-63-5 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

17
[ 88095-61-8 ]
[ 1557232-69-5 ]
[ 1557232-67-3 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

18
[ 88095-61-8 ]
[ 1557235-76-3 ]
[ 1557235-77-4 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

19
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f ]indazole-3-carboxamide [ No CAS ]
N-(1-benzyl-1H-pyrazol-4-yl)-1,4,4a,5,5a,6-hexahydrocyclopropa[f ]indazole-3-carboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

20
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f ]indazole-3-carboxamide [ No CAS ]
N-(1-benzyl-1H-pyrazol-4-yl)-5a-methyl-1,4,4a,5,5a,6-hexahydrocyclopropa[f ]indazole-3-carboxamide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

21
[ 88095-61-8 ]
[ 1557232-08-2 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727
[2]Journal of Medicinal Chemistry,2015,vol. 58,p. 3806 - 3816

22
[ 88095-61-8 ]
[ 1557232-13-9 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

23
[ 88095-61-8 ]
[ 1557232-63-9 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

24
[ 88095-61-8 ]
[ 1557232-34-4 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

25
[ 88095-61-8 ]
[ 1557232-37-7 ]

Reference： [1]Journal of Medicinal Chemistry,2014,vol. 57,p. 5714 - 5727

26
[ 2075-46-9 ]
[ 620-05-3 ]
[ 88095-61-8 ]

Yield	Reaction Conditions	Operation in experiment
98%	With potassium carbonate; In N,N-dimethyl-formamide; at 25℃; for 16h;	General procedure: To a stirred solution of 4-nitroimidazole or 4-nitropyrazole (1.00 g, 8.84 mmol) in DMF (6.00 mL) at 25C were added K2CO3 (1.47 g, 10.6 mmol) and alkyl iodide(10.6 mmol). After stirring for 16 h at 25 C, the reactionmixture was treated with water (15 mL) and EtOAc (20 mL)and transferred to a 125 mL separatory funnel. The organiclayer was collected and the aqueous layer was extracted withEtOAc (25 mL × 2). The combined organic layers werewashed with brine (20 mL), dried over sodium sulfate andfiltered. The filtrate was concentrated, and the residue waspurified by flash column chromatography to provide thecorresponding alkyl azole.
	With potassium carbonate; In N,N-dimethyl-formamide; at 20℃;	General procedure: A mixture of methyliodide (12 mmol), 1a (6 mmol) and K2CO3 (9 mmol) in DMF (6 mL) was stirred overnight at room temperature. Then the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (25 mL × 3). The organic layer was washed with aqueous saturated sodium bicarbonate, dried by sodium sulfate, ltered and concentrated in vacuum. Purication by ash column chromatography gave the desired product 2a (2a-2c).A mixture of iodobenzene (6.82 mmol), 1a (0.70 g, 6.20 mmol), 8-hydroxyquinoline (0.09 g, 0.62 mmol), cuprous iodide (0.18 g, 0.62 mmol) and potassium carbonate (1.73 g, 12.40 mmol) in DMSO (10 mL) was heated at 135 oC for 20 h. After cooling to room temperature, the reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate. The organic layer was washed with aqueous saturated sodium bicarbonate, dried by sodium sulfate, filtered and concentrated in vacuo. Purification by flash column chromatography gave the desired products 2d (2d-2g).

Reference： [1]Bulletin of the Korean Chemical Society,2014,vol. 35,p. 3009 - 3014
[2]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390
[3]ChemMedChem,2018,vol. 13,p. 2558 - 2566

27
[ 41492-05-1 ]
[ 88095-61-8 ]
1-benzyl-5-(4-butylphenyl)-4-nitro-1H-pyrazole [ No CAS ]
1-benzyl-3,5-bis(4-butylphenyl)-4-nitro-1H-pyrazole [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%; 7%	With palladium diacetate; potassium carbonate; tricyclohexylphosphine tetrafluoroborate; In toluene; at 100℃; for 18h;Inert atmosphere;	General procedure: To a 8 mL glass vial equipped with a magnetic stirbar were sequentially added K2CO3 (207 mg, 1.5 mmol), the nitroazole substrate (0.50 mmol), aryl halide (0.50 mmol oras indicated), toluene (0.50 M or 1.0 M), Pd(OAc)2 (5.60mg, 0.025 mmol) and [PCy3H]BF4 (18.4 mg, 0.050 mmol).The reaction mixture was purged with nitrogen through aTeflon-lined cap. Then the cap was replaced with a newTeflon-lined solid cap. The reaction vial was moved to a preheatedreaction block. After stirring for 18 h at the indicatedtemperature, the reaction mixture was cooled to 25 C and concentrated. The residue was purified by flash column chromatography to provide the desired arylated product.
62%; 25%	With palladium diacetate; potassium carbonate; tricyclohexylphosphine tetrafluoroborate; Trimethylacetic acid; In toluene; at 120℃; for 18h;Inert atmosphere;	General procedure: To a 8 mL glass vial equipped with a magnetic stirbar were sequentially added K2CO3 (207 mg, 1.5 mmol), the nitroazole substrate (0.50 mmol), aryl halide (0.50 mmol oras indicated), toluene (0.50 M or 1.0 M), Pd(OAc)2 (5.60mg, 0.025 mmol) and [PCy3H]BF4 (18.4 mg, 0.050 mmol).The reaction mixture was purged with nitrogen through aTeflon-lined cap. Then the cap was replaced with a newTeflon-lined solid cap. The reaction vial was moved to a preheatedreaction block. After stirring for 18 h at the indicatedtemperature, the reaction mixture was cooled to 25 C and concentrated. The residue was purified by flash column chromatography to provide the desired arylated product.

Reference： [1]Bulletin of the Korean Chemical Society,2014,vol. 35,p. 3009 - 3014
[2]Bulletin of the Korean Chemical Society,2014,vol. 35,p. 3009 - 3014

28
[ 88095-61-8 ]
[ 1557233-35-8 ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 3806 - 3816

29
[ 88095-61-8 ]
C₂₀H₁₉F₂N₅O [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2015,vol. 58,p. 3806 - 3816

30
[ 21040-45-9 ]
[ 88095-61-8 ]
1-benzyl-5-cinnamyl-4-nitro-1H-pyrazole [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

31
[ 7217-71-2 ]
[ 88095-61-8 ]
1-benzyl-5-cinnamyl-4-nitro-1H-pyrazole [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

32
[ 591-87-7 ]
[ 88095-61-8 ]
5-allyl-1-benzyl-4-nitro-1H-pyrazole [ No CAS ]
(E)-1-benzyl-4-nitro-5-(prop-1-en-1-yl)-1H-pyrazole [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697
[2]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

33
[ 820-71-3 ]
[ 88095-61-8 ]
1-benzyl-5-(2-methylallyl)-4-nitro-1H-pyrazole [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

34
[ 100-39-0 ]
[ 88095-61-8 ]
C₁₇H₁₅N₃O₂ [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

35
[ 100-44-7 ]
[ 88095-61-8 ]
C₁₇H₁₅N₃O₂ [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2015,vol. 80,p. 690 - 697

36
[ 536-74-3 ]
[ 88095-61-8 ]
(E)-1-benzyl-5-(1,4-diphenylbut-1-en-3-yn-2-yl)-4-nitro-1H-pyrazole [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2018,vol. 2018,p. 2645 - 2650

37
[ 536-74-3 ]
[ 88095-61-8 ]
1-benzyl-4-nitro-5-(phenylethynyl)-1H-pyrazole [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2018,vol. 2018,p. 2645 - 2650

38
[ 88095-61-8 ]
2- (3-(3-chlorophenyl)-1H-pyrazol-1-yl)-N-(1-benzyl-1H-pyrazol-4-yl)acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390

39
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-2-(3-(pyridin-2-yl)-1H-pyrazol-1-yl)acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390

40
[ 88095-61-8 ]
2-(3,4-dimethoxyphenyl)-N-(1-benzyl-1H-pyrazol-4-yl)acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390

41
[ 88095-61-8 ]
C₁₂H₁₂BrN₃O [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390

42
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-2-(1H-indol-1-yl)acetamide [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2018,vol. 28,p. 2382 - 2390

43
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-3-(3-phenylureido)benzamide [ No CAS ]

Reference： [1]ChemMedChem,2018,vol. 13,p. 2558 - 2566

44
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-3-(3-(4-(trifluoromethyl)phenyl)ureido)benzamide [ No CAS ]

Reference： [1]ChemMedChem,2018,vol. 13,p. 2558 - 2566

45
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) benzamide [ No CAS ]

Reference： [1]ChemMedChem,2018,vol. 13,p. 2558 - 2566

46
[ 88095-61-8 ]
N-(1-benzyl-1H-pyrazol-4-yl)-5-(tert-butyl)isoxazole-3-carboxamide [ No CAS ]